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Abstract 
Background 
Although alcohol use disorders (AUD) are known to increase the relative 
risk of all-cause and some cause-specific mortalities, the absolute mortality 
rates of the AUD population are unknown. Such knowledge would benefit 
planners of the provision of services for this population, including in 
prioritising the identification and/or treatment of diseases likely to cause 
their death. 
Methods 
We conducted a systematic review of studies in English, reporting the 
cause-specific mortality rates among people treated for AUD. Number of 
deaths by cause, and total person-years of follow-up were extracted. All-
cause and cause-specific mortality rates per 1000 person-years were meta-
analysed assuming random effects. 
Results 
31 studies were included. Participants were mainly middle-aged males. The 
quality of studies was generally good. 6,768 all-cause deaths in 276,990.7 
person-years of follow-up (36,375 patients) were recorded and the pooled 
all-cause mortality rate was 27.67/1000 person years (py) (95% 
confidence interval (CI) 23.9, 32.04). The commonest cause of death in the 
AUD population was cardiovascular disease (CVD) (6.9/1000py (95%CI 
5.61, 8.49)), followed by gastrointestinal deaths (5.63/1000py (95%CI 
4.1, 7.74)), unnatural deaths (4.95/1000py (95%CI 4.01, 6.09)), 
neoplasms, respiratory diseases and substance use disorders. 
Conclusions 
Patients with AUD have increased rates of all-cause and cause-specific 
mortality compared to the general population. Like the general population, 
they are most likely to die of CVD. In contrast to the general population, 
gastrointestinal and unnatural deaths are the next most common causes of 
death. We believe these facts should be considered when planning 
healthcare services for patients with AUD.  
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Introduction 
Alcohol use disorders (AUD), a clinical term describing alcohol dependence 
and alcohol abuse 1, are one of the most prevalent mental disorders 
worldwide, affecting an estimated 4.1% of the global population aged 15 
to 64 years 2. 
AUDs are recognised to increase the risk of all-cause mortality and a 
number of specific causes of death 3–5. Roerecke has conducted two meta-
analyses of the relative risk of all-cause or cause-specific mortality in this 
population. The first estimated that the risk of all-cause mortality in male 
patients with AUD in treatment settings is 3.38 times that of the general 
population, whereas in women it is 2.57 6.  
In the second, Roerecke assessed the cause-specific standardized mortality 
ratios (SMR) of the same population. They found that the conditions that 
have the greatest relative risk of mortality in men with AUD are mental 
health disorders, digestive diseases and injuries (19.8, 10.74, and 6.64 
times the risk within the standard population respectively) 7. 
Although relative mortality measures (such as the SMR, or relative 
mortality risk), being measures of effect, are useful in demonstrating an 
association between AUD and deaths from specific causes, the ‘absolute’ 
mortality rate, being a measure of disease frequency, would be of benefit 
to public health practitioners in planning or prioritising the allocation of 
resources to provide suitable health interventions to prevent deaths from 
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these causes in the AUD population. This is because this measure provides 
a more accurate estimate of disease burden within populations 8,9, and is 
used and often required in population health needs/status assessments 
10,11. As yet, no systematic review of the absolute mortality rates of the 
AUD population is available. 
We therefore aimed to address this knowledge gap by systematically 
reviewing the cause-specific mortality rates in the AUD population.  
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Methods 
Search strategy 
We conducted a systematic literature search in the Medline (via OVID), 
EMBASE (via OVID), CINAHL and PsycINFO databases from inception to 
March 2015. We used broad terms related to the concepts of ‘alcohol’ AND 
‘misuse’ AND ‘death', both through use of free text and indexed search 
terms. The full search strategy is available as Supplemental Information, 
Table S1. 
We included papers which fulfilled all the following criteria: 1) reported 
results from cohort studies, or intervention trials with a non-intervention 
arm; 2) contained patients treated for AUD; 3) included study endpoints of 
cause-specific mortality and presented rates on the basis of person-time, 
or other information that allowed transformations to this measure and 4) 
were published in English. 
We also searched for additional articles to include by checking the reference 
lists of included studies, and the titles or abstracts of conference or 
symposia for the last five years of Alcohol Research UK; the American 
Society of Addiction Medicine; the Association for Medical Education and 
Research in Substance Abuse; the Medical Council on Alcohol; the National 
Institute on Drug Abuse (NIDA) International Forum; and the Society for 
the Study of Alcohol. 
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We largely followed published guidelines on the conduct and reporting of 
systematic reviews: one in general 12, and another of observational studies 
in particular 13. 
Screening  
Title, abstract and full text screening were performed independently by two 
reviewers (AA and KF for titles, and AA and TC for the other stages). 
Disagreements were resolved through consensus. Any remaining 
discrepancies were discussed with a 3rd reviewer (TC for titles, and KF for 
the other stages). 
Where multiple articles reported the same study, we included the one 
reporting the highest number of person-years. 
Data Extraction 
Data from all included studies were extracted by AA using a standardised 
extraction tool containing the following items: 
Study report characteristics: Author; year of the study; title of the article; 
location of study. 
Quality appraisal: Quality appraisal was conducted using an adaptation of 
the Newcastle Ottawa Scale (NOS) 14 (available in Supplemental 
Information, Table S2). This adaptation omitted questions relating to the 
non-exposed cohort as they were inapplicable in our review. Adequacy of 
 5 
length of follow up was set as being six months: the definition of chronicity 
or long-term as used by the World Organization of Family Doctors 15. 
Mortality data: we extracted (for combined-genders) number of patients 
with AUD at risk, number of deaths in total and by cause, and person-years 
of follow up. 
We categorised the reported causes of deaths firstly into eleven broad 
groups. These are: neoplasms; cardiovascular; neurological; respiratory; 
gastrointestinal; genitourinary; endocrinological and metabolic; 
immunological diseases; unnatural or violent deaths; substance use 
disorders; and infectious diseases. We also grouped the causes of deaths 
into nine narrow groupings. These were: cancers; coronary heart disease; 
stroke; hypertension; cirrhosis; diabetes mellitus; suicide; alcohol-use 
disorder; and Human Immunodeficiency Virus infection or Acquired 
Immune Deficiency Syndrome (HIV/AIDS). These disease groupings were 
not predetermined, but instead formed pragmatically, using the disease 
terminologies or the diagnostic codings reported in the included studies. 
Analysis 
Mortality rates were obtained by dividing the number of deaths by the 
reported total person-years at risk, and were reported in 1000 person-year 
(py) units (with 95% confidence intervals (CI)). All analyses are presented 
for all ages and both sexes combined, as separate results could not be 
extracted from the majority of the original study reports. Information 
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provided in other ways was, where possible, transformed to enable us to 
calculate mortality rates and 95%CIs. These transformations are adapted 
from those used by Degenhardt et al 16. The full list of transformations is 
described in Supplemental Information S3. 
The extracted information on cause-specific number of deaths and person-
years for each cause of death was used to generate standard errors of 
cause-specific mortality. Mortality rates and their respective standard 
errors were pooled across studies for each cause of death category in turn. 
For each study and each cause of death, the natural logarithm of the 
mortality rate (number of deaths/1000 person-years) was estimated, with 
standard errors computed assuming a Poisson distribution for the number 
of deaths. These were then pooled assuming random effects using a 
DerSimonian-Laird random-effect model to allow for between-study 
heterogeneity, which was estimated by the I2 statistic 17,18. We present the 
meta-analysed combined-gender crude cause-specific mortality rates by 
broad and narrow cause of death groups for each study. 
We also present the specific causes of death as proportions of all-cause 
death (referred to here as proportional mortality (PM)). This measure may 
be useful for public health practitioners who might not have access to 
sufficient information to form the denominators of risk or rate measures 
19,20. 
Cause-specific mortality proportions for a given study were calculated by 
dividing the number of deaths due to specific cause of death by the number 
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of all-cause deaths in the study (and presented as percentages). The 
proportional mortalities and their respective standard errors were pooled 
across studies in a similar process to the one described above. 
Finally we present a comparison of the age-standardised mortality rate per 
1000 population between the current study and the 2013 WHO Global 
Burden of Disease (GBD) Study which reports the 1-year mortality rates 
for the 2010 global general population21 for the top five causes of death in 
this review. 
All analyses were conducted using Stata 14 22.  
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Results  
Flow of included papers 
The initial search identified 11644 unique citations. Title and abstract 
screening excluded 10446 of these. Inter-rater agreement for the title 
screen was moderate (κ=0.49) and for the abstract screen substantial 
(κ=0.74)23. All disagreements were resolved by consensus with no referrals 
needed for decision by a third reviewer. 
The screening of the full text of the remaining 386 papers resulted in 355 
study reports being rejected for the following reasons: were not cohort 
studies or trials with non-intervened arms (n=42); were not studies of 
patients who received treatment for AUD (n=135); did not report cause-
specific mortality (n=137); data were presented in a form which could not 
allow calculation of mortality rates in person years (n=27); or contained 
data from a study included previously in this review (n=14). 
No additional relevant published studies were identified from the references 
of included papers or the searches of conference titles or abstracts. 
31 studies were thus identified for inclusion in this review. 
A flow diagram for the selection of studies, and the bibliography of studies 
excluded after full text evaluation, are presented in Supplemental 
Information Figure S4 and Bibliography S5 respectively. 
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Characteristics of included studies 
The 31 cohort studies included in this review reported 36,375 patients 
treated for AUD (combined-genders), followed up for a total of 276,990.7 
person-years. 6768 all-cause deaths were recorded 24–54. 
Fourteen studies were from Europe (eight from western or northern Europe 
and six from southern Europe), nine from North America, five from Asia 
(four from the advanced economies of Japan and Taiwan, and one from Sri 
Lanka), two from New Zealand and one from South Africa. The maximum 
follow-up time of the studies ranged from three to 42 years (mean=14.06 
years). The average follow-up observed per participant ranged from 1.5 to 
18 years (mean=7.48 years). 
All 28 studies that reported gender breakdown had at least 50% male 
participants (range: 50-100%; median=79.98%). Six studies had only 
male participants. All 28 studies reporting age at baseline had an average 
age of study participants of at least 30 (range: 34.7-59; median: 44). 
Table 1 summarises the characteristics of included studies. 
Table 1: Characteristics of individual studies 
[TABLE 1 HERE] 
Key  
1: mean 
2: median 
3: mode 
4: actual loss to follow-up not reported or could not be estimated. This figure represents the maximum possible 
loss to follow up assuming that all those who did not die were lost to follow up. 
a: Fuster, D. et al. “Impact of Hepatitis C Virus Infection on the Risk of Death of Alcohol-Dependent Patients.” 
Journal of Viral Hepatitis 22.1 (2014): 18–24. Journal of Viral Hepatitis. 
na: not reported or available 
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Risk of bias assessment  
Overall, the quality of included studies was good, with all included papers 
scoring 4 or more from a total of 6. All 31 studies scored fully for questions 
related to ascertainment of AUD status and death, and adequacy of length 
of follow up. Twelve papers did not report whether the sampled cohort was 
representative of all the patients receiving therapy for AUD, and 16 papers 
did not report the proportion of the cohort that was lost to follow up. The 
quality assessment of the included studies is presented in Supplemental 
Information Table S6. 
Meta-analysis of all-cause mortality rates 
All-cause mortality among these predominantly middle-aged adults was 
27.67/1000py (95%CI 23.9, 32.04) (Figure 1). The heterogeneity was high 
at I2=96.9%. This estimate remained high when subgroup analyses were 
conducted using the following variables: demographic (average age; 
percent of males; country income level), clinical (the AUD subtype (AUD in 
general vs alcohol dependence only); mortality rate size), and 
methodological (study quality; whether there was a reported diagnostic 
system used to categorise causes of deaths). 
[FIGURE 1 HERE] 
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Figure 1: Forest plot of pooled crude mortality rates: All-Cause 
Mortality 
Meta-analysis of cause-specific mortality rates 
The diagnostic coding or terminology used to define the broad and narrow 
cause of death groups are presented in Supplemental Information: Tables 
S7.1 and S7.2. 
The forest plots of pooled crude mortality rates for the five most common 
cause of death are presented in Supplemental Information Tables and 
Figures S8.1 to S8.5. Details of all-cause and cause-specific mortality rates 
for each study are presented in Supplemental Information Tables S9.1 and 
S9.2. We did not present the pooled rates for two specific causes of deaths 
(hypertension and HIV) as only two studies contributed data. 
The highest cause-specific pooled mortality rate was that for cardiovascular 
diseases (6.9/1000py (95%CI 5.61, 8.49)), followed by gastrointestinal 
diseases (5.63/1000py (95%CI 4.1, 7.74), unnatural deaths (4.95/1000py 
(95%CI 4.01, 6.09)), neoplasms (4.47/1000py (95%CI 3.34, 6.00)), and 
respiratory diseases (1.42/1000py (95%CI 0.96, 2.10)). 
This is summarized in table 2. 
Table 2: All-cause and cause-specific mortality rates 
[TABLE 2 HERE] 
Note: the table reports pooled crude rates, for combined-genders 
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Meta-analysis of the proportional mortality of specific causes of death 
Presenting this as cause-specific proportional mortality, the largest 
proportional mortality was recorded by cardiovascular diseases, making up 
24.55% of deaths (95%CI 20.14, 28.96). This was followed by 
gastrointestinal diseases (20.35% (95%CI 16.39, 24.31)), unnatural 
deaths (18.2% (59%CI 15.07, 21.34)), neoplasms (14.93% (95%CI 
11.35, 18.51)), and substance use disorders (5.24% (95%CI 3.76, 6.71)). 
This is summarized in Table 3. 
Table 3: Proportional mortality of specific causes of death 
[TABLE 3 HERE] 
Note: the table reports pooled proportions, for combined-genders 
Comparison of rates and proportional mortality to those of the global 
population 
Lastly, table 4 compares the differences in the pattern of specific causes of 
death in the alcohol treatment population as distinct from the 2010 global 
general population 21. The all-cause mortality in the alcohol treatment 
population is more than three times that of the general population 
(27.67/1000py vs. 8.8/1000). The population of patients with AUD share 
cardiovascular diseases as the most common cause of death (mortality rate 
(MR): 6.9 vs 2.93/1000py; proportional mortality (PM): 24.55 vs 31.53%). 
However, gastrointestinal deaths, consisting mostly of cirrhosis (MR: 5.63 
vs 0.38/1000py; PM: 20.35 vs 6.5%), and unnatural deaths (MR: 4.95 vs 
0.7/1000py; PM: 18.2 vs 8.7%) rank higher in terms of mortality rates as 
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well as proportional mortality in patients with AUD than they do in the 
general population, supplanting the rank of neoplasms and infectious 
diseases. 
Table 4: Comparisons of meta-analysed mortality rates and 
proportional mortality versus those reported in the WHO GBD 
2013 study for all-cause deaths and the top five most common 
causes of deaths. 
[TABLE 4 HERE] 
Note: this table reports crude combined-gender rates and proportions 
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Discussion 
We have presented pooled estimates from the published health 
literature of the all-cause and cause-specific mortality rates of AUD 
treatment patients, and established the most common causes of 
deaths for this population. 
Evidence from 36,375 patients, followed up for a total of 276,990.7 
person-years, across 31 studies reveal that the crude all-cause 
mortality rates in this population, formed largely of middle-aged 
adults, is 27.67/1000py. The specific causes of death with the highest 
mortality rates are cardiovascular diseases (6.9/1000py), followed by 
gastrointestinal diseases (5.63/1000py), unnatural deaths 
(4.95/1000py), neoplasms (4.47/1000py), and respiratory diseases 
(1.42/1000py). 
Strengths and limitations 
The presentation of absolute mortality rates may render our results 
more useful in the prioritization and planning of health services for 
specific populations (such as patients with AUD in this case) than 
would the relative risk measures 8,9, reported by previous reviews of 
this subject 6,7. 
We found that the quality of the studies included in this review was 
generally good. All the studies include good ascertainment of alcohol 
use disorders, linkage to national registers for deaths, and loss to 
 15 
follow up (where reported) was low (i.e. <20% 55). Where loss to 
follow up was not explicitly reported 31,41, we believe that the loss to 
follow up was unlikely to differ greatly to the other studies, as these 
studies also recorded outcomes via linkage to national registration 
systems where mortality ascertainment is largely complete 56,57. 
There are nevertheless some biases that we should consider when 
interpreting our study. 
Firstly, there is the matter of the generalisability of the participants 
of the included studies. We have concentrated on populations 
receiving treatment for AUD as this is a fairly accessible AUD 
population, and one likely to have had AUD carefully assessed. Given 
that the included studies were predominantly conducted in advanced 
economies, recruited mostly middle-aged males, and that we 
reported rates for combined genders, the findings of this review are 
likely to be generalisable to similar AUD populations and not to other 
AUD populations with different demographic, clinical, socioeconomic 
or other characteristics. An example of such a population might be 
that described by Gunnarsdottir et al. 58, where the AUD population 
was sampled in the emergency care setting, and consisted of a lesser 
proportion of males (63.7%) than ours, and had mortality rates less 
than those found in this review (e.g. all-cause mortality 12.62 vs 
28.08/1000py). 
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Secondly, we found significant heterogeneity in the meta-analysed 
estimates of pooled crude mortality rates. Sources of this 
heterogeneity may include differences in the demographic or clinical 
characteristics of participants 59. Certainly, there was variation in age 
ranges of participants, ethnic make-up of the range of countries, and 
the income classification of countries (and these, across different time 
periods) in the included studies.  
Variation in the AUD treatment regimens themselves might 
contribute to variation in outcome. Methodological diversity is also 
possible since there could be variation in the coding of causes of 
deaths: whether as ‘mode of death’ (e.g. cardiac arrest) or as ‘the 
underlying cause of death’ (e.g. chronic kidney disease) 60. The 
included studies do not specify which of these two approaches was 
used. 
Being a diagnosis made up of either of two elements (alcohol harmful 
use/abuse, or dependence) under DSM IV 1, it is probable that the 
effect of these two subsets of AUD on mortality is not homogenous. 
Under DSM V, the distinction between these two subgroups within 
AUD are removed. The change in diagnostic coding may therefore 
hide a potentially important difference in the mortality rate between 
these two AUD subgroups, and it is important therefore to recognize 
the need for similarly robust estimates of the mortality experience of 
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both subgroups. Unfortunately, currently available data does not 
permit this. 
Nevertheless, it has been shown that those with alcohol dependence 
are more likely to be categorized as AUD under DSM IV, and those 
with alcohol abuse less so. This results in AUD treatment populations 
under DSM V having similar prelavences to those of the AUD 
population under DSM IV 61. Patients treated for AUD under DSM V 
are therefore likely to be similar to patients being treated for AUD 
under DSM IV, and one could reasonably predict that the mortality 
rates would be similar. 
Considering the likelihood of alcohol dependence being classified as 
AUD, as noted above, and that those with alcohol dependence are 
more likely to be treated compared to those with alcohol abuse, it 
follows that our AUD treatment population are those likely to have 
alcohol dependence. Our results therefore are more likely to reflect 
mortality in alcohol dependence rather than alcohol abuse.  
Comparison to previous literature 
There have not been previous systematic reviews of mortality rates 
of alcohol misusers with which to compare our findings. This is 
perhaps unsurprising as Dickersin has previously highlighted that 
systematic reviews of “descriptive information” (e.g. disease 
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mechanisms, incidence and prevalence of a condition) are fewer than 
those of analytical research (i.e. of interventions) 62.  
We have demonstrated that the all-cause mortality rates were more 
than three times (3.14) that of the general population figures quoted 
in the 2013 WHO Global Burden of Disease Study 21. Comparing this 
to Roerecke’s 2013 study, they observed a not too dissimilar risk 
estimate in his study (3.38) 6, lending support to the validity of our 
results.  
Additionally, we found that although both the AUD and general 
populations share CVDs as the most common cause of death, 
gastrointestinal and unnatural deaths are much more common in the 
AUD population than they are in the general population.  
When compared to the ranks of conditions with the highest 
standardized mortality ratios (SMR), Roerecke found that these were 
firstly mental health diseases, followed by digestive diseases, 
injuries, endocrine diseases, and respiratory diseases. Cardiovascular 
diseases and cancers were causes of death with the 6th and 7th 
highest SMR 7. Clearly, this demonstrates that the ranks of the SMRs 
or other relative risks or rates of specific causes of death do not 
necessarily correspond to those of absolute risks or rates. 
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Policy implications 
The potential importance of this work is as much in informing what 
patients with AUD do not die of as in what they do. We have shown 
that CVD remains the commonest cause of death in this group, and 
so those planning or delivering health care to these patients, should 
not neglect to assess markers of cardiovascular risk, nor 
opportunities to reduce that risk. However, the reduced rates of 
malignant deaths relative to gastrointestinal or unnatural ones, 
suggest that in this group it may be sensible to devote more 
resources to liver disease, for example, than to cancer screening. As 
non-invasive methodologies to screen for advancing liver disease 
have now been developed, attention to the earlier detection of this 
may provide opportunities to benefit these patients, for instance, via 
prophylaxis against variceal bleeding. Such action has clear potential 
for benefit when one considers that the currently available evidence 
suggests nearly half of liver disease in England presents with 
decompensation (such as variceal bleeding or ascites) 63. Such 
screening for specific causes of deaths is currently in place for 
populations suffering from certain other conditions at increased risk 
of mortality (e.g. chronic kidney disease in those with type 2 
diabetes) 64,65. 
Other than informing the prioritisation of finite resources, and its 
resulting influence on clinical practice, this work could also help public 
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health professionals. Those involved in health planning can use the 
pooled mortality rate information provided here, for instance in health 
needs assessments 66, to compare against those observed in their 
jurisdictions, or to estimate the amount of resources they might need 
to allocate to patients with AUD in their own locations in a year. 
Finally, based on the demonstration that those conditions with high 
relative rates of mortality do not necessarily also have high absolute 
mortality rates, it is pertinent that health researchers respond to the 
need for public health relevance by increasing the reporting of 
measures of frequency or occurrence, and not only relative measures 
of association. 
Conclusions 
Our systematic review presents pooled crude absolute all-cause and 
cause-specific mortality rates. Like the general population, patients 
under treatment for AUD are most likely to die of CVDs. However, in 
contrast to the general population, the ranks of the other common 
causes of deaths differ, with gastrointestinal and unnatural deaths 
being the next most common causes of deaths. We believe that these 
facts should be borne in mind when planning healthcare services for 
those with AUDs. 
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